Medical Cannabis

Bedrocan: What Went Wrong? – The Administrators’ Account

This is the final part of our three-part series examining the various, conflicting accounts of Bedrocan’s bankruptcy declaration.

This is the final part of our three-part series examining the various, conflicting accounts of Bedrocan’s bankruptcy declaration. Health Minister Sophie Hermans’ account and founder and former chairman Tjalling Erkelens’ account are covered in Part 1 and Part 2.

Arno Gras and Floris Verduijn, the court-appointed administrators (trustees) in the Bedrocan bankruptcy, filed the First Public Bankruptcy Report with the Rechtbank Noord-Nederland on November 09. Supervised by judge D.J. Klijn, the report is the first in what will be a series of periodic public filings documenting the trustees’ handling of the estate. 

Given their sole motivation is to maximise the value of the estate for creditors and assess the viability of a restart, their account provides a relatively neutral baseline. 

What caused the bankruptcy

The trustees mirror Erkelens’ assertion that the commercial arrangement between Bedrocan and the BMC was a framework agreement for the purchase and supply of medicinal cannabis, not as a service agreement. 

They similarly identify the BMC’s refusal to take delivery of stock it had ordered from 2023 onwards as the underlying cause of the insolvency cascade that ended in bankruptcy. The ‘freezer incident’ of September 2023 appears in the report as a consequence of the commercial failure between BMC and its contracted grower, rather than its cause, supporting Erkelens’ ‘weaponisation’ framing. 

Financial conduct

The report sets out Bedrocan Nederland’s revenue and EBIT profits. Revenue topped €19.94m in 2024, €20.50m in 2025 and €12.49m in the first nine months of 2026. EBIT, meanwhile, was €1.35m in 2024, €2.58m in 2025 and €1.91m to September 2026. This directly contradicts the Minister’s characterisation of 2026 as a year in which only ‘a few orders’ were running, and corroborates Erkelens’s figure of more than €12.4m in turnover up to the point of bankruptcy.

On the suspension of payments, the trustees record in Chapter 1.5 of their report that Rabobank, Bedrocan’s main pledgeholder, was willing to finance a restructuring and continuation of the business, on the condition that the BMC guarantee it would pay in full for invoices for batches it had ordered and that had passed quality control. 

After the BMC took the position that the batches ‘were not necessary for its statutory task’, and declined to cooperate with alternative buyers the trustees proposed, the trustees petitioned the court on October 07 to convert the suspension of payments into bankruptcy. This again directly supports Erkelens’ account and contradicts the minister’s framing that the Cabinet decided against assisting because the restart’s success was uncertain.

After the bankruptcy was declared, the BMC agreed with the trustees to take delivery of batches it had itself ordered and declined to pay for during the suspension of payments, and to resell them to a market party found by Bedrocan’s commercial team. 

The minister’s letter acknowledges that the state cooperated in part with this resale but does not dwell on the fact that these were the same batches BMC had earlier declared not necessary for its statutory task. On this point, the trustees’ record strongly corroborates Erkelens’s reading that BMC’s refusal during the suspension was a strategic act rather than a judgement about the stock’s commercial value.

Future supply and patient impact

The report sets out the physical stock position at the point of bankruptcy. Bedrocan Nederland held 340 kg of finished Regime 1 product, 390 kg of Regime 1 cultivation in progress, and 250 kg of Regime 2 product. Total holding of approximately 730 kg confirms Erkelens’s figure. All 69 employees of Bedrocan Nederland B.V. were dismissed on October 08. 

The trustees describe the restart they have selected as the preferred route for preserving the continuity of medicinal cannabis supply to patients in the Netherlands and in Bedrocan’s historical export destinations, including the United Kingdom, Germany, Italy and Finland. 

What comes next?

The trustees have selected a restart bid for Bedrocan Nederland B.V. and are awaiting the supervisory judge’s approval. The identity of the selected bidder is not disclosed in the public report. The Canadian shares and intellectual property held by the Bedrocan group have been sold to the German/Dutch cannabis company Becanex for €200,000, with the trustees’ approval and subject to the supervisory judge’s confirmation. Further periodic public reports will follow as the estate is wound up and the restart, if approved, is implemented.

TopicsadministratorsBankruptcyBedrocanEBITRevenuesTrustee

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.